News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dako A/S (Acquired by Agilent Technologies, Inc.) (A) Enters Collaboration With Eli Lilly and Company (LLY) for Development of Companion Diagnostics



1/7/2013 9:45:13 AM

GLOSTRUP, DENMARK--(Marketwire - January 07, 2013) - Dako, an Agilent Technologies company, announced today it has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly.

The agreement constitutes a framework for collaboration between Dako and Lilly with a focus on the Lilly oncology pipeline.

"Building lasting partnerships is a cornerstone to Dako," says Lars Holmkvist, CEO of Dako and senior vice president, Agilent. "I warmly welcome Lilly, and I am excited about what we may accomplish together for the benefit of patients worldwide. This agreement heralds our mutual commitment to fighting cancer."

Companion diagnostics are increasingly in demand with the recognition that personalized medicine may provide a way to improve patient care and manage health-care costs by targeting treatments to individuals more likely to benefit from specific therapies.

"Tailored therapies are a key component of Lilly's strategy of providing improved outcomes for individual patients," says Greg Zdechlik, chief operating officer, Diagnostics, Eli Lilly and Company. "We look forward to collaborating with Dako in an effort to develop oncology companion diagnostics for patients worldwide who are waiting."

Dako has a strong heritage of developing diagnostic tests in collaboration with pharmaceutical companies. The collaboration with Lilly is another example of Dako's position in the clinical diagnostics market as a strong partner for developing diagnostic tests for use in conjunction with medicines.

About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at www.dako.com.

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.


EDITORIAL CONTACT:

Maia Fredtoft Sochting
Dako
+45 25 46 10 83
maia.sochting@dako.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES